Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies

WINDSOR, ON / ACCESSWIRE / March 21, 2016 / The Wealthy Biotech Trader (or “WBT”), is an investment newsletter focused on presenting everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks, which are making news and subsequent market moves. WBT would like to shed some light on the bubble among the big pharma companies and draw attention to smaller, yet highly innovative companies making their presence felt in the medical device sector. We will focus on our highlighted company, Endonovo Therapeutics, Inc. (OTCQB: ENDV), which we will compare to and contrast to a few others in the space.

Over the past four years, both small and big pharma companies have invested billions of dollars into R&D, with little to show in terms of a viable drug. Despite the lack of results, speculations have boosted shares and this segment is said to be in a bubble. On the other hand, medical device companies have emerged as a group with significant potential.

Developing Devices Based on NASA Technology

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. These devices are based on the Time-Varying Electromagnetic Field (TVEMF) technology originally developed at NASA.

Endonovo’s bioelectronics technology uses electromagnetic pulses to deliver electrical stimulation to the nervous system and cells.

Immunotronics™ platform: This is a non-invasive, non-implantable bioelectronic device for preventing and treating vital organ failure through the reduction of inflammation and cell death, and the promotion of regeneration. Endonovo’s technology was previously identified in pre-clinical studies to be an innovative approach for treating acute inflammation.

Endonovo’s bioelectronic device uses a different approach than others in the field; it is a non-implantable device that uses a pulsed electromagnetic field to deliver electrical stimulation, rather than implantable electrodes.

The company is targeting inflammatory conditions in vital organs and has set its initial concentration on treating inflammation in the liver. If Endonovo can treat inflammation in vital organs then its technology would truly be a game changer as inflammation is regarded as the root of all disease.

Why Medical Device Companies Are Becoming Even More Interesting Versus Drugs

The great news is that Medical Device Companies have just become even more interesting. Traditionally, investors have viewed medical device companies as largely non-innovative “me too” technologies aspiring to create a better mouse trap, so to speak. As such, it’s not surprising 90 percent of yearly FDA reviewed devices are via the 510(k) process, which requires a company demonstrate their device is substantially equivalent to another legally (predicate) marketed device. Essentially, the Company must show it does not have an innovative technology in order to use this regulatory pathway.

However, as technology continues to accelerate, a new batch of truly innovative medical devices are beginning to emerge. One particular field that is attracting a tremendous amount of attention from investors and big pharma, such as GlaxoSmithKline is bio-electronic medicine, which seeks to treat diseases using electrical pulses.

These innovative technologies have also attracted the help of the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH), who have committed $240 million over six years to encourage researchers to collaborate on these technologies.

At the core of bio-electronic medicine are electrical signals utilized by the nervous system and cells to communicate information. In short, these innovative medical devices use electrical signals to produce a biological effect in the body to treat diseases.

Bio-electronic technologies can be used to record, stimulate and block neural signaling. These technologies hold the potential to change the way diseases, injuries and conditions such as rheumatoid arthritis, Crohn’s disease, diabetes, solid organ failure and even cancer are treated.

These devices, if successful, hold the potential to replace billions of dollars of drugs with less expensive and potentially safer devices.

Where to Invest?

While the prospects may be bright, investment needs to be discerning. According to experts, it may be more prudent to look for a company that is investing in innovation and is focused on a new technology. The reason being that less differentiated products would face stiff competition, while more innovative devices have typically offered a better performance, not only shifting market share but also allowing these companies to command a premium for their products and earn better margins.

A Few Other Companies Making Headway in the Medical Device & Healthcare Space

TrovaGene, Inc. (NASDAQ: TROV) is a molecular diagnostic company developing technology for the detection and monitoring of cell-free DNA in urine. The company’s precision cancer monitoring platform aims to provide critical clinical information beyond the current standard of care. Hedge fund First Eagle Investment Management LLC recently acquired a new stake in TrovaGene, valued at approximately $2,031,000.

Progressive Care, Inc. (OTC: RXMD), through its subsidiary PharmCo, LLC, provides prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities. The company reported more than $1.1 million in revenues in February 2016, representing an increase of 18% over the performance in February 2015. PharmCo has delivered a strong performance over January and February this year, despite the first 2 months of the year being the “deductible season,” during which most deductibles are in effect before insurance benefits are paid to providers.

Cardiovascular Systems Inc. (NASDAQ: CSII) is a medical device company focused on developing and commercializing treatments for vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The company reported $41.40 million in revenue for the latest quarter. On February 23, major shareholder Camber Capital Management LLC acquired a new stake in Cardiovascular Systems for a total consideration of $1,887,500.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter, Facebook, SMS as well as newswire.

GET BREAKING NEWS FROM US:

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z
Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
Email: Info@WealthyVentureCapitalist.com

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

The Wealthy Biotech Trader’s parent company has been compensated $150,000 by Endonovo Therapeutics Inc. in the form of a 6 month restricted convertible promissory note and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.

Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this art.

SOURCE: The Wealthy Biotech Trader

ReleaseID: 438044